Literature DB >> 27687979

Mouse models in oncoimmunology.

Laurence Zitvogel1,2, Jonathan M Pitt1, Romain Daillère1, Mark J Smyth3, Guido Kroemer4,5,6,7,8,9.   

Abstract

Fundamental cancer research and the development of efficacious antineoplastic treatments both rely on experimental systems in which the relationship between malignant cells and immune cells can be studied. Mouse models of transplantable, carcinogen-induced or genetically engineered malignancies - each with their specific advantages and difficulties - have laid the foundations of oncoimmunology. These models have guided the immunosurveillance theory that postulates that evasion from immune control is an essential feature of cancer, the concept that the long-term effects of conventional cancer treatments mostly rely on the reinstatement of anticancer immune responses and the preclinical development of immunotherapies, including currently approved immune checkpoint blockers. Specific aspects of pharmacological development, as well as attempts to personalize cancer treatments using patient-derived xenografts, require the development of mouse models in which murine genes and cells are replaced with their human equivalents. Such 'humanized' mouse models are being progressively refined to characterize the leukocyte subpopulations that belong to the innate and acquired arms of the immune system as they infiltrate human cancers that are subjected to experimental therapies. We surmise that the ever-advancing refinement of murine preclinical models will accelerate the pace of therapeutic optimization in patients.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27687979     DOI: 10.1038/nrc.2016.91

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN: 1474-175X            Impact factor:   60.716


  106 in total

Review 1.  Defining the optimal murine models to investigate immune checkpoint blockers and their combination with other immunotherapies.

Authors:  M F Sanmamed; C Chester; I Melero; H Kohrt
Journal:  Ann Oncol       Date:  2016-02-23       Impact factor: 32.976

Review 2.  Combining immunotherapy and targeted therapies in cancer treatment.

Authors:  Matthew Vanneman; Glenn Dranoff
Journal:  Nat Rev Cancer       Date:  2012-03-22       Impact factor: 60.716

Review 3.  Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential.

Authors:  Padmanee Sharma; James P Allison
Journal:  Cell       Date:  2015-04-09       Impact factor: 41.582

4.  Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer.

Authors:  Daniel Schramek; Andreas Leibbrandt; Verena Sigl; Lukas Kenner; John A Pospisilik; Heather J Lee; Reiko Hanada; Purna A Joshi; Antonios Aliprantis; Laurie Glimcher; Manolis Pasparakis; Rama Khokha; Christopher J Ormandy; Martin Widschwendter; Georg Schett; Josef M Penninger
Journal:  Nature       Date:  2010-09-29       Impact factor: 49.962

5.  Nivolumab and Urelumab Enhance Antitumor Activity of Human T Lymphocytes Engrafted in Rag2-/-IL2Rγnull Immunodeficient Mice.

Authors:  Miguel F Sanmamed; Inmaculada Rodriguez; Kurt A Schalper; Carmen Oñate; Arantza Azpilikueta; Maria E Rodriguez-Ruiz; Aizea Morales-Kastresana; Sara Labiano; Jose L Pérez-Gracia; Salvador Martín-Algarra; Carlos Alfaro; Guillermo Mazzolini; Francesca Sarno; Manuel Hidalgo; Alan J Korman; Maria Jure-Kunkel; Ignacio Melero
Journal:  Cancer Res       Date:  2015-06-25       Impact factor: 12.701

Review 6.  Neutralizing tumor-promoting chronic inflammation: a magic bullet?

Authors:  Lisa M Coussens; Laurence Zitvogel; A Karolina Palucka
Journal:  Science       Date:  2013-01-18       Impact factor: 47.728

7.  Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors.

Authors:  François Ghiringhelli; Lionel Apetoh; Antoine Tesniere; Laetitia Aymeric; Yuting Ma; Carla Ortiz; Karim Vermaelen; Theocharis Panaretakis; Grégoire Mignot; Evelyn Ullrich; Jean-Luc Perfettini; Frédéric Schlemmer; Ezgi Tasdemir; Martin Uhl; Pierre Génin; Ahmet Civas; Bernhard Ryffel; Jean Kanellopoulos; Jürg Tschopp; Fabrice André; Rosette Lidereau; Nicole M McLaughlin; Nicole M Haynes; Mark J Smyth; Guido Kroemer; Laurence Zitvogel
Journal:  Nat Med       Date:  2009-09-20       Impact factor: 53.440

8.  Adaptive immunity maintains occult cancer in an equilibrium state.

Authors:  Catherine M Koebel; William Vermi; Jeremy B Swann; Nadeen Zerafa; Scott J Rodig; Lloyd J Old; Mark J Smyth; Robert D Schreiber
Journal:  Nature       Date:  2007-11-18       Impact factor: 49.962

Review 9.  PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations.

Authors:  Weiping Zou; Jedd D Wolchok; Lieping Chen
Journal:  Sci Transl Med       Date:  2016-03-02       Impact factor: 17.956

10.  Contribution of IL-17-producing gamma delta T cells to the efficacy of anticancer chemotherapy.

Authors:  Yuting Ma; Laetitia Aymeric; Clara Locher; Stephen R Mattarollo; Nicolas F Delahaye; Pablo Pereira; Laurent Boucontet; Lionel Apetoh; François Ghiringhelli; Noëlia Casares; Juan José Lasarte; Goro Matsuzaki; Koichi Ikuta; Bernard Ryffel; Kamel Benlagha; Antoine Tesnière; Nicolas Ibrahim; Julie Déchanet-Merville; Nathalie Chaput; Mark J Smyth; Guido Kroemer; Laurence Zitvogel
Journal:  J Exp Med       Date:  2011-03-07       Impact factor: 14.307

View more
  110 in total

Review 1.  Humanized mice for immune checkpoint blockade in human solid tumors.

Authors:  Henry Yip; Carl Haupt; Grace Maresh; Xin Zhang; Li Li
Journal:  Am J Clin Exp Urol       Date:  2019-10-15

Review 2.  Mouse Models of Oncoimmunology in Hepatocellular Carcinoma.

Authors:  Erin Bresnahan; Katherine E Lindblad; Marina Ruiz de Galarreta; Amaia Lujambio
Journal:  Clin Cancer Res       Date:  2020-04-23       Impact factor: 12.531

3.  Label-Free Multimodal Multiphoton Intravital Imaging.

Authors:  Jaena Park; Haohua Tu; Marina Marjanovic; Stephen A Boppart
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 4.  Tumor targeting via EPR: Strategies to enhance patient responses.

Authors:  Susanne K Golombek; Jan-Niklas May; Benjamin Theek; Lia Appold; Natascha Drude; Fabian Kiessling; Twan Lammers
Journal:  Adv Drug Deliv Rev       Date:  2018-07-19       Impact factor: 15.470

Review 5.  Opportunities and challenges in the immunological therapy of pediatric malignancy: a concise snapshot.

Authors:  Francesco Ceppi; Maja Beck-Popovic; Jean-Pierre Bourquin; Raffaele Renella
Journal:  Eur J Pediatr       Date:  2017-08-12       Impact factor: 3.183

6.  Immunosurveillance and immunoediting in MMTV-PyMT-induced mammary oncogenesis.

Authors:  Emilie T E Gross; Semi Han; Prasantha Vemu; Carlos D Peinado; Martin Marsala; Lesley G Ellies; Jack D Bui
Journal:  Oncoimmunology       Date:  2016-12-14       Impact factor: 8.110

Review 7.  Trial watch: Immune checkpoint blockers for cancer therapy.

Authors:  Claire Vanpouille-Box; Claire Lhuillier; Lucillia Bezu; Fernando Aranda; Takahiro Yamazaki; Oliver Kepp; Jitka Fucikova; Radek Spisek; Sandra Demaria; Silvia C Formenti; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2017-08-31       Impact factor: 8.110

Review 8.  Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors.

Authors:  Lorenzo Galluzzi; Juliette Humeau; Aitziber Buqué; Laurence Zitvogel; Guido Kroemer
Journal:  Nat Rev Clin Oncol       Date:  2020-08-05       Impact factor: 66.675

9.  From Famine to Feast: Developing Early-Phase Combination Immunotherapy Trials Wisely.

Authors:  Daphne Day; Arta M Monjazeb; Elad Sharon; S Percy Ivy; Eric H Rubin; Gary L Rosner; Marcus O Butler
Journal:  Clin Cancer Res       Date:  2017-09-01       Impact factor: 12.531

10.  Characterization of immune cell subtypes in three commonly used mouse strains reveals gender and strain-specific variations.

Authors:  Jonathan A Hensel; Vinayak Khattar; Reading Ashton; Selvarangan Ponnazhagan
Journal:  Lab Invest       Date:  2018-10-23       Impact factor: 5.662

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.